Trial reportFrontiers in psychiatry2026
High-frequency repetitive transcranial magnetic stimulation is associated with sustained improvement in cannabis use disorder: a one-year, two-phase, three-arm randomized study.
Trial report in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05292547 (Substance Misuse To Psychiatric Disorders-Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Substance Misuse To Psychiatric Disorders-Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: High-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (DLPFC) shows promise in treating substance use disorders, but its efficacy for cannabis use disorder (CUD) is less well established. This 12-month, two-phase, three-arm, prospective, open-label study evaluated the short- and long- term effects of high-frequency rTMS over the left DLPFC in individuals with moderate to severe CUD across three treatment schedules. Methods: In the "active rTMS phase", 18 participants (12 men, mean age 24.89) were first randomized in a 1:1:1 ratio to receive 20 rTMS sessions with 2400 pulses of 15 Hz per session over three treatment schedules for 2, 4, or 5 weeks. All participants then entered a 12-month observational "maintenance phase" without further active rTMS treatments. Outcome assessments included Severity of Dependence Scale (SDS) score, MCQ-SF, CUD severity, frequency of use, abstinence, and CPQ at baseline, post-treatment, and at 3, 6, and 12 months. Results: All rTMS sessions were well tolerated with no significant adverse events. Across all groups, rTMS was associated with improved psychological dependence and reduced craving, DSM-5 defined CUD severity, use frequency, and related problems over 12 months (all Conclusions: These findings provide support for the safety and the potential short- and long-term treatment effects associated with high-frequency rTMS over the DLPFC for reducing cannabis dependence and severity of CUD. Further large-scale studies are needed to differentiate the optimal treatment scheduling when using rTMS for CUD. This study was registered at clinicaltrials.gov (NCT05292547). Clinical Trial Registration: clinicaltrials.gov, identifier NCT05292547.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.